NUMERO: #20240707

Título: RETROSPECTIVE ANALYSIS OF CONSERVATIVE TREATMENT OF UNICYSTIC AMELOBLASTOMA

Nome do Apresentador: Gustavo Luiz Alkmin PAIVA

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Cirurgia e traumatologia bucomaxilofacial

Resumo: Aims: The aim of this study is to describe a retrospective series of cases of unicystic ameloblastoma treated with conservative surgery and with a long follow-up.
Material and methods: Over a 24-year period, clinicopathological and therapeutic data of unicystic ameloblastoma treated with conservative surgery were retrospectively reviewed. Unicystic ameloblastoma cases were classified based on three criteria: 1) clinical findings during biopsy: presence of a cystic lesion or positive aspiration puncture; 2) 3D imaging with contrast: well-defined unicystic lesion; 3) histopathological examination consistent with ameloblastoma. Marsupialization was performed as an initial surgical procedure following incisional biopsy. After marsupialization and a period of decompression, the lesion was enucleated, followed by cryotherapy or peripheral ostectomy.
Results: This study included 25 cases with a mean age of 18.6 years (range 4-45 years). All cases underwent conservative surgery, with 21 cases initially undergoing marsupialization before definitive surgery. The mean follow-up period was 85 months (range 7-276 months), with an average marsupialization duration of 11 months. Only one case experienced recurrence after 7.8 months following marsupialization and peripheral ostectomy.
Conclusion: Conservative treatment for unicystic ameloblastoma appears to be a reliable option with low rates of recurrence and minimal morbidity, particularly in younger patients.

Autor 1:  Gustavo Luiz Alkmin PAIVA

E-mail 1:  [email protected]

Autor 2:   Alan Roger dos Santos Silva

E-mail 2:  [email protected]

Autor 3 :  Pablo Agustin Vargas

E-mail 3:  [email protected]

Autor 4:  Gustavo Grothe Machado

E-mail 4:  [email protected]

Autor 5:  André Caroli Rocha

E-mail 5:  [email protected]